The Icahn School of Medicine at Mount Sinai (ISMMS) has been awarded a $584,214 Project Grant under the National Institute of Diabetes and Digestive and Kidney Diseases' (NIDDK) Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The funding will support the development of a solid-state fermentation platform for manufacturing defined live biotherapeutic products (LBPs) comprised of cultured bacterial strains. This aims to streamline the production of scalable microbial therapeutics for treating infectious and inflammatory diseases, such as recurrent Clostridioides difficile infection and ulcerative colitis. The project will also explore genetic engineering strategies to enhance the functionality of these bacterial consortia. Overall, the grant will advance ISMMS's capabilities in defined LBP manufacturing and accelerate the translation of new live microbial therapies into clinical trials over the award period from February 2025 to January 2029.
Generated 3/4/25, 5:50 AM